secwatch.observer — SEC 8-K summary
======================================

Issuer:     MADRIGAL PHARMACEUTICALS, INC. (MDGL)
CIK:        0001157601
Form:       8-K
Filed at:   2025-12-11T23:59:59+00:00
Accession:  0001628280-25-056533
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Madrigal appoints Rita Thakkar as SVP and Chief Accounting Officer, effective Jan 12, 2026
--------------------------------------------------------------------------------

- Rita Thakkar joins as principal accounting officer; Mardi Dier remains CFO and principal financial officer.
- Thakkar previously SVP Global Business Operations at Bristol Myers Squibb and Chief Audit Officer at BMS and Celgene.
- Annual base salary of $450,000 with target bonus of 40% of salary; initial equity grant valued at $1,932,000.
- Equity award composed of 70% time-based RSUs (4-year vest) and 30% stock options (graded vest over 4 years).
- Severance agreement provides 12 months salary and bonus upon qualifying separation, with enhanced benefits on change of control.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1157601/000162828025056533/0001628280-25-056533-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1157601/000162828025056533/mdgl-20251205.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-056533

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer